Female Sex Hormone Augmentation is Effective for Menopausal Psychosis

Translated Titles





余男文(Nan-Wen Yu);蕭美君(Mei-Chun Hsiao);劉嘉逸(Chia-Yih Liu)

Key Words

停經後精神病 ; Premelle ; 雌激素 ; menopausal psychosis ; Premelle ; estrogen



Volume or Term/Year and Month of Publication

24卷2期(2010 / 06 / 01)

Page #

146 - 149

Content Language


Chinese Abstract

背景:更年期婦女有較高出現精神病症狀的機會。更年期或是停經後精神病用抗精神病藥物治療無效時,加上女性荷爾蒙可能可改善療效。病例報告:我們提出一例50歲首次出現精神病症狀的晚發型精神分裂女性個案,其精神病症狀使用3種抗精神病藥物治療反應並不佳,且在抗精神病藥物劑量增加之後出現明顯錐體外症候群副作用。於是我們併用Premelle2.5(conjugated estrogen 0.625+medroxyprogesterone 2.5mg)每日一顆,其精神病症狀獲得相當程度的控制與改善,並以隔日一顆與抗精神病藥合用治療兩年。在停止使用Premelle成單線使用抗精神病藥物後,其精神病症狀再度復發;再次投與Premelle即再次獲得改善,於一年後停止使用Premelle,個案繼續以抗精神病藥維持治療,病況穩定。結論:雌激素能調節多巴胺,有類似抗精神病劑之作用,故於停經後精神病婦女為一有效之加強治療。

English Abstract

Background: Perimenopausal women may have an increased vulnerability to psychosis. Antipsychotic drugs are considered effective for acute and maintenance treatment of menopausal psychosis. In those patients who respond poorly to antipsychotic agents, estrogen augmentation may be also beneficial. Case report: We present a 50-year-old woman experiencing psychotic symptoms with onset one year after the menopause. The patient with positive psychotic symptoms did not respond well to three different antipsychotic drugs at adequate dosage and duration. But she responded with a combination of antipsychotic drug and Premelle 2.5 (conjugated estrogen 0.625+medroxyprogesterone 2.5mg) daily, and achieved a satisfactory treatment response. The patient’s psychotic symptoms were re-emerged after discontinuation of Premelle and were resolved after resuming Premelle treatment. Conclusion: Estrogen modulates the dopamine system in a mechanism similar to neuroleptic drugs and is an effective augmentation treatment for menopausal psychosis.

Topic Category 醫藥衛生 > 社會醫學
  1. Ahokas, A.,Aito, M.,Rimon, R.(2000).Positive treatment effect of estradiol in postpartum psychosis: a pilot study.J Clin Psychiatry,61,166-9.
  2. DiPaolo, T.(1994).Modulation of brain dopamine transmission by sex steroids.Rev Neurosci,5,27-41.
  3. Ghaemi, S.N.,Hsu, D.J.,Rosenquist, K.J.,Pardo, T.B.,Goodwin, F.K.(2006).Extrapyramidal side effects with atypical neuroleptics in bipolar disorder.Prog Neuro-Psychopharmacol Biol Psychiatry,30,209-13.
  4. Kritzer, M.F.,Kohama, S.G.(1998).Ovarian hormones influence the morphology, distribution, and density of tyrosine hydroxylase immunoreactive axons in the dorsolateral prefrontal cortex of adult monkeys.J Comput Neurol,395,1-17.
  5. Lindamer, L.A.,Lohr, J.B.,Caligiuri, M.P.,Jeste, D.V.(2001).Relationship of gender and age at onset of schizophrenia to severity of dyskinesia.J Neuropsychiat Clin Neurosci,13,399-402.
  6. Lobo, R.A.,Shoupe, D.,Roy, S.,Paul, W.(1984).Central and peripheral metabolites of norepinephrine and dopamine in postmenopausal women.Am J Obst Gyn,149,548-52.
  7. Mahe'', V.,Dumaine. A.(2001).Oestrogen withdrawal associated psychoses.Acta Psychiatr Scand,104,323-31.
  8. Riecher-Rossler, A.,Hafner, H.,Stumbalum, M.(1994).Can estradiol modulate schizophrenia symptomatology?.Schizophr. Bull,20,203-13.
  9. Sara, A.,Gardiner, B.A.,Mary, F.(2004).Pilot study on the effect of estrogen replacement therapy on brain dopamine transporter availability in healthy, post-menopausal women.Am J Geriatr Psychiatry,12,621-30.
  10. Usall, J.(2003).Use of estrogens in the treatment of mental disorders.Actas Esp Psyquiatr,31,199-204.